The Medical Letter on Drugs and Therapeutics
Peginterferon Alfa-2b (Sylatron) for Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Peginterferon Alfa-2b (Sylatron) for Melanoma
The FDA has approved peginterferon alfa-2b (Sylatron – Merck) for adjuvant treatment of node-positive melanoma after surgical resection. Pegylated interferon has a longer duration of action than interferon alfa-2b (Intron A), which is also...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Peginterferon Alfa-2b (Sylatron) for Melanoma
Article code: 1373c
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.